Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | NOTUM | Q6P988 | 6/20 | 0.36 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.35 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.34 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.33 |
| ▸ | ARG1 | P05089 | 1/20 | 0.33 |
| ▸ | ARG2 | P78540 | 1/20 | 0.33 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.33 |
| ▸ | CLPP | Q16740 | 1/20 | 0.33 |
| ▸ | MMP13 | P45452 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6702598 | 0.82 | SIGMAR1 (0.36) | ALDH1A1TSHRL3MBTL1S1PR1S1PR3 | |
| SCHEMBL6700621 | 0.76 | ALDH1A1 (0.37) | ALDH1A1TSHRL3MBTL1HTTSIGMAR1 | |
| SCHEMBL6704242 | 0.76 | PTGER4 (0.36) | ALDH1A1TSHRL3MBTL1HTTSIGMAR1 | |
| SCHEMBL6700597 | 0.72 | KDM4E (0.50) | ALDH1A1PTGER4MMP13 | |
| SCHEMBL6704368 | 0.70 | ALDH1A1 (0.35) | ALDH1A1TSHRL3MBTL1S1PR1S1PR3 | |
| SCHEMBL6292195 | 0.70 | ALDH1A1 (0.38) | ALDH1A1TSHRL3MBTL1NOTUMS1PR1 | |
| SCHEMBL6702248 | 0.70 | MMP13 (0.43) | ALDH1A1PTGER4MMP13 | |
| SCHEMBL6699473 | 0.70 | MAOB (0.45) | ALDH1A1L3MBTL1S1PR3PTGER4CLPP | |
| SCHEMBL6700329 | 0.69 | ALDH1A1 (0.35) | ALDH1A1TSHRL3MBTL1NOTUMHTT | |
| SCHEMBL6702369 | 0.68 | KDM4E (0.46) | ALDH1A1S1PR3SIGMAR1PTGER4CLPP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2004014916-A1 | PYRIMIDINE FUSED BICYCLIC METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-02-19 | — | — | WO | claimed |
| US-20040038994-A1 | Pyrimidine fused bicyclic metalloproteinase inhibitors | WILSON MICHAEL WILLIAM (US) | 2004-02-26 | — | — | US | disclosed |
| WO-2004014916-A1 | PYRIMIDINE FUSED BICYCLIC METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040038994-A1 | Pyrimidine fused bicyclic metalloproteinase inhibitors | MMP9, MMP1, MMP2 | ALDH1A1 221/4885TSHR 4387/4885L3MBTL1 2759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.